Double Blind, Randomized, Placebo-controlled Study of Safety, Tolerability, and Pharmacokinetics of Ascending Doses of XC7 After Single and Multiple Oral Administration in Healthy Volunteers
Latest Information Update: 23 Sep 2021
At a glance
- Drugs XC 7 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors NP Therapeutics
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 02 Apr 2021 Planned End Date changed from 1 Feb 2021 to 1 Apr 2021.
- 02 Apr 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Apr 2021.